We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Horizon Pharma, Vidara Therapeutics International Ltd Acquisition to Become Horizon Pharma plc
News

Horizon Pharma, Vidara Therapeutics International Ltd Acquisition to Become Horizon Pharma plc

Horizon Pharma, Vidara Therapeutics International Ltd Acquisition to Become Horizon Pharma plc
News

Horizon Pharma, Vidara Therapeutics International Ltd Acquisition to Become Horizon Pharma plc

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Horizon Pharma, Vidara Therapeutics International Ltd Acquisition to Become Horizon Pharma plc"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Horizon Pharma, Inc. and Vidara Therapeutics International Ltd. today announced they have entered into a definitive agreement under which Horizon Pharma will acquire Vidara through a reverse merger for stock and cash valued at approximately $660 million. Horizon Pharma plc will be the name of the resulting company. Horizon Pharma plc will be organized under the laws of Ireland with a portfolio of four products marketed primarily in the United States. The proposed transaction has been unanimously approved by both companies' boards of directors. Pursuant to the agreement, Vidara will combine with Horizon Pharma, Inc. with approximately 74 percent of Horizon Pharma plc's ordinary shares to be exchanged for Horizon Pharma, Inc.'s common shares, with Horizon surviving the merger. The shareholders of Vidara will retain approximately 26 percent of Horizon Pharma plc and receive $200 million in cash, subject to certain adjustments.

Strategic and financial benefits of the transaction:
•    Accelerated transformation of Horizon to a profitable specialty pharma company;
•    Expected pro forma combined, full year 2014 revenues of $250 to $265 million and EBITDA(1) of $65 to $75 million;
•    Expanded revenue base to include Horizon Pharma's DUEXIS®, VIMOVO® and RAYOS® marketed in the U.S., Vidara's ACTIMMUNE marketed in the U.S. and Horizon's LODOTRA® marketed outside the U.S.;
•    Tax efficient corporate structure enhanced to support Horizon's organic growth and acquisition strategy.

"The addition of ACTIMMUNE complements our commercial business model focused on targeted promotion to primary care physicians and specialists," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma. "The combined company would have a portfolio of four proprietary products and an international platform that builds on our strategy of organic growth and acquisitions. We look forward to working with the Vidara team to bring our companies together to accelerate the creation of shareholder value."

Advertisement